aTyr Pharma Inc (NASDAQ:LIFE) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.63 and traded as high as $3.41. aTyr Pharma shares last traded at $3.40, with a volume of 7,594 shares.
A number of research firms have recently weighed in on LIFE. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Citigroup set a $4.00 price objective on shares of aTyr Pharma and gave the stock a “hold” rating in a report on Friday, August 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $12.07.
The business has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $1.63. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.88 and a quick ratio of 3.88.
A number of institutional investors and hedge funds have recently bought and sold shares of LIFE. Wedbush Securities Inc. boosted its position in aTyr Pharma by 158.7% during the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 41,271 shares during the period. Renaissance Technologies LLC grew its holdings in aTyr Pharma by 19.8% during the second quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 305,314 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in aTyr Pharma by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 33,702 shares during the last quarter.
About aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Featured Article: Stock Portfolio Tracker
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.